Use of Intravitreal Bevacizumab in Eyes With Choroidal Neovascularization Secondary to Angioid Streaks

OCT, Visual Outcome and Angiographic Analysis of Choroidal Neovascularization in Six Eyes With Angioid Streaks Treated With a Single Intravitreal Injection of Bevacizumab

Status

Terminated

Phases

Phase 3

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT00599820

Enrollment

Unknown

Registered

2008-01-24

Start date

2005-11-30

Completion date

2006-05-31

Last updated

2024-06-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Angioid Streaks, Choroidal Neovascularization

Keywords

Angioid Streaks, Choroidal Neovascularization, Bevacizumab

Brief summary

Intravitreal Bevacizumab is an effective treatment for choroidal neovascularization secondary to Angioid Streaks

Detailed description

A consecutive case series of patients with angioid streaks that developed subfoveal choroidal neovascularization were treated with a primary 2.5 mg injection of Bevacizumab (Avastin) intravitreally. All patients were evaluated with BCVA at 1, 2 , 4 and 12 weeks and OCT and fluoresceine angiography at month 1 and 3. (Patients will be follow 6 months)

Interventions

DRUGIntravitreal Bevacizumab

Study design

Allocation

NON_RANDOMIZED

Intervention model

SINGLE_GROUP

Primary purpose

TREATMENT

Masking

NONE

Eligibility

Sex/Gender

ALL

Healthy volunteers

Inclusion criteria

* Clinical diagnosis of Angioid Streaks * Choroidal neovascularization associated * Untreated patients or patients treated once with PDT

Exclusion criteria

* Ocular surgery excepting uncomplicated phacoemulsification * Glaucoma or any other ocular pathology

Design outcomes

Primary

Measure	Time frame
BCVA	—
Fluoresceine Angiography	—
Optical Coherence Tomography	—

Countries

Mexico

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026